Calidi Biotherapeutics (CLDI) Cash & Equivalents (2022 - 2026)

Calidi Biotherapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $219000.0 for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 97.72% year-over-year to $219000.0; the TTM figure through Dec 2025 stood at $219000.0 (down 97.72% YoY), while the FY2025 annual figure was $219000.0, down 97.72% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $219000.0, down from $10.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $10.6 million in Q1 2025, with the low at $102000.0 in Q2 2025.
• The 4-year median for Cash & Equivalents is $1.9 million (2024), against an average of $4.3 million.
• Peak annual rise in Cash & Equivalents reached 827.38% in 2025, while the deepest fall reached 97.72% in 2025.
• Calidi Biotherapeutics' Cash & Equivalents stood at $218000.0 in 2022, then soared by 794.04% to $1.9 million in 2023, then surged by 392.1% to $9.6 million in 2024, then plunged by 97.72% to $219000.0 in 2025.
• Business Quant data shows CLDI's Cash & Equivalents at $219000.0 in Q4 2025, $10.4 million in Q3 2025, and $102000.0 in Q2 2025.